GSK3B and metabolic dysfunction-associated steatotic liver disease: The results revealed that the multi-anti-NAFLD mechanisms of SYTZD might be associated with enhancement of ESR1, p-GSK-3β protein and inhibition of mTOR, FASN, HIF-1α, VEGFA proteins.